Advanced search
Publication Cover
Leukemia & Lymphoma Volume 2, 1990 - Issue 3-4
Submit an article Journal homepage
37
Views
53
CrossRef citations to date
0
Altmetric
Original Article

Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies

Martin J. S Dyer Departments of Haematology and Pathology, University of Cambridge, Cambridge, UK
,
Geoff Hale Departments of Haematology and Pathology, University of Cambridge, Cambridge, UK
,
Robert Marcus Departments of Haematology and Pathology, University of Cambridge, Cambridge, UK
&
Herman Waldmann Departments of Haematology and Pathology, University of Cambridge, Cambridge, UK
Pages 179-193 | Received 30 Nov 1989, Published online: 01 Jul 2009

Citations (53)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Samuel A Jacobs & Kenneth A Foon. (2005) Monoclonal antibody therapy of leukaemias and lymphomas. Expert Opinion on Biological Therapy 5:9, pages 1225-1243.
Read now
Marco Montillo, Timo Schinkoethe & Thomas Elter. (2005) Eradication of Minimal Residual Disease with Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients: The Need for a Standard Method of Detection and the Potential Impact of Bone Marrow Clearance on Disease Outcome. Cancer Investigation 23:6, pages 488-496.
Read now
Roger G Owen. (2001) Treatment options in Waldenström’s macroglobulinaemia: the role of the purine analogues. Expert Opinion on Pharmacotherapy 2:6, pages 945-952.
Read now
A. Khorana, P. Bunn, P. McLaughlin, J. Vose, C. Stewart & M. S. Czuczman. (2001) A Phase II Multicenter Study of CAMPATH-1H Antibody in Previously Treated Patients with Nonbulky Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 41:1-2, pages 77-87.
Read now
Brian K. Link & George J. Weiner. (1998) Monoclonal Antibodies in the Treatment of Human B-Cell Malignancies. Leukemia & Lymphoma 31:3-4, pages 237-249.
Read now
S. C. Tang, K. Hewitt, M. D. Reis & N. L. Berinstein. (1996) Immunosuppressive Toxicity of CAMPATH®1H Monoclonal Antibody in the Treatment of Patients with Recurrent Low Grade Lymphoma. Leukemia & Lymphoma 24:1-2, pages 93-101.
Read now
Sally Greenaway, Anthony J. Henniker, Mark Walsh & Kenneth F. Bradstock. (1994) A Pilot Clinical Trial of Two Murine Monoclonal Antibodies Fixing Human Complement in Patients with Chronic Lymphatic Leukaemia. Leukemia & Lymphoma 13:3-4, pages 323-331.
Read now
S. H. Lim & J. J. Ifthikharuddin. (1994) Autoimmune Thrombocytopenic Purpura Complicating Lymphoproliferative Disorders. Leukemia & Lymphoma 15:1-2, pages 61-64.
Read now

Articles from other publishers (45)

Federica R. Achini-Gutzwiller, Marco W. Schilham, Erik G. J. von Asmuth, Anja M. Jansen-Hoogendijk, Cornelia M. Jol-van der Zijde, Maarten J. D. van Tol, Robbert G. M. Bredius, Tayfun Güngör, Arjan C. Lankester & Dirk Jan A. R. Moes. (2023) Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study. Blood Advances 7:16, pages 4462-4474.
Crossref
Sanford Kempin, Zhuoxin Sun, Neil E. Kay, Elisabeth M. Paietta, Joseph J. Mazza, Rhett P. Ketterling, Olga Frankfurt, David F. Claxton, Joel N. Saltzman, Gordan Srkalovic, Natalie S. Callander, Gerald Gross & Martin S. Tallman. (2019) Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903). Acta Haematologica 142:4, pages 224-232.
Crossref
Suguru Fukuhara & Kensei Tobinai. 2017. Chemotherapy for Leukemia. Chemotherapy for Leukemia 99 122 .
Ryuichi Hotta, Masahiro Ohira, Toshiharu Matsuura, Izumi Muraoka, Panagiotis Tryphonopoulos, Ji Fan, Akin Tekin, Gennaro Selvaggi, David Levi, Phillip Ruiz, Camillo Ricordi, Rodrigo Vianna, Hideki Ohdan, Herman Waldmann, Andreas G. Tzakis & Seigo Nishida. (2016) CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment. PLOS ONE 11:8, pages e0161618.
Crossref
Jeremy L. Warner & Jon E. Arnason. (2012) Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Therapeutic Advances in Hematology 3:6, pages 375-389.
Crossref
Sambasiva P. Rao, Jose Sancho, Juanita Campos-Rivera, Paula M. Boutin, Peter B. Severy, Timothy Weeden, Srinivas Shankara, Bruce L. Roberts & Johanne M. Kaplan. (2012) Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis. PLoS ONE 7:6, pages e39416.
Crossref
Claire E. Dearden & Estella Matutes. (2006) Alemtuzumab in T-cell lymphoproliferative disorders. Best Practice & Research Clinical Haematology 19:4, pages 795-810.
Crossref
Bruce D. Cheson. (2005) Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy 55:2, pages 188-196.
Crossref
Thomas S. LinIan W. FlinnRama ModaliTeresa A. LehmanJennifer WebbSharon WaymerMollie E. MoranMargaret S. LucasSherif S. FaragJohn C. Byrd. (2005) FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 105:1, pages 289-291.
Crossref
Claire Dearden. (2004) Alemtuzumab in Peripheral T-Cell Malignancies. Cancer Biotherapy and Radiopharmaceuticals 19:4, pages 391-398.
Crossref
I F Khouri, M Albitar, R M Saliba, C Ippoliti, Y C Ma, M J Keating & R E Champlin. (2004) Low-dose alemtuzumab (Campath®) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplantation 33:8, pages 833-837.
Crossref
Michael M. Quigley, Kelly J. Bethel, Robert W. Sharpe & Alan Saven. (2003) CD52 expression in hairy cell leukemia. American Journal of Hematology 74:4, pages 227-230.
Crossref
G. A. Kennedy, J. F. Seymour, M. Wolf, H. Januszewicz, J. Davison, C. McCormack, G. Ryan & H. M. Prince. (2003) Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. European Journal of Haematology 71:4, pages 250-256.
Crossref
Soren U. NielsenEdward G. Routledge. (2002) Human T cells resistant to complement lysis by bivalent antibody can be efficiently lysed by dimers of monovalent antibody. Blood 100:12, pages 4067-4073.
Crossref
K. R. RaiC. E. FreterR. J. MercierM. R. CooperB. S. MitchellE. A. StadtmauerP. SantábarbaraB. WackerL. Brettman. (2002) Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine. Journal of Clinical Oncology 20:18, pages 3891-3897.
Crossref
RE Birhiray, G Shaw, S Guldan, D Rudolf, D Delmastro, P Santabarbara & L Brettman. (2002) Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H. Leukemia 16:5, pages 861-864.
Crossref
Claire Dearden. (2002) Monoclonal Antibody Therapy of Haematological Malignancies. BioDrugs 16:4, pages 283-301.
Crossref
Helen T Wu. (2016) Alemtuzumab (Campath-1H, Campath1) for the treatment of lymphoid malignancies: chronic lymphocytic leukemia and T-cell prolymphocytic leukemia. Journal of Oncology Pharmacy Practice 7:4, pages 133-140.
Crossref
S. M. A. Rizvi, B. J. Allen, Z. Tian, G. Goozee & S. Sarkar. (2001) In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer . Colorectal Disease 3:5, pages 345-353.
Crossref
Donald Bunjes. (2000) T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983?1999. Transfusion Science 23:2, pages 151-162.
Crossref
Thomas A Davis. (2000) Monoclonal antibody-based therapy of lymphoid neoplasms: What's on the horizon?. Seminars in Hematology 37, pages 34-42.
Crossref
R. G. Owen, S. A. Johnson & G. J. Morgan. (2000) Waldenstr�m's macroglobulinaemia: Laboratory diagnosis and treatment. Hematological Oncology 18:2, pages 41-49.
Crossref
Geoff Hale & Herman Waldmann. 2000. Diagnostic and Therapeutic Antibodies. Diagnostic and Therapeutic Antibodies 243 266 .
Hannah J. Gould, Graham A. Mackay, Sophia N. Karagiannis, Carol M. O'Toole, Philip J. Marsh, Barbara E. Daniel, Leslie R. Coney, Vincent R. Zurawski, Michel Joseph, Monique Capron, Michael Gilbert, George F. Murphy & Robert Korngold. (1999) Comparison of IgE and IgG antibody-dependent cytotoxicityin vitro and in a SCID mouse xenograft model of ovarian carcinoma. European Journal of Immunology 29:11, pages 3527-3537.
Crossref
Lia Ginaldi, Massimo De Martinis, Estella Matutes, Nahla Farahat, Ricardo Morilla, Martin J.S. Dyer & Daniel Catovsky. (1998) Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. Leukemia Research 22:2, pages 185-191.
Crossref
Y. Bastion, N. Dhedin, P. Felman & B. Coiffier. 1997. The Teaching Cases from Annals of Oncology. The Teaching Cases from Annals of Oncology 57 62 .
Jan Brissinck & Stephen J. Russell. (1996) 9 Vaccine strategies in non-Hodgkin's lymphomas. Baillière's Clinical Haematology 9:4, pages 799-817.
Crossref
Delia C. Baquiran, Lucy Dantis & Joan McKerrow. (1996) Monoclonal antibodies: Innovations in diagnosis and therapy. Seminars in Oncology Nursing 12:2, pages 130-141.
Crossref
P.N. Boyd, A.C. Lines & A.K. Patel. (1995) The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Molecular Immunology 32:17-18, pages 1311-1318.
Crossref
Eric L. Matteson, David E. Yocum, E. William St. Clair, Antonio A. Achkar, Michael S. Thakor, Mary R. Jacobs, Anita E. Hays, Catherine K. Heitman & Jeffrey M. Johnston. (2005) Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody campath‐1h administered by daily subcutaneous injection. Arthritis & Rheumatism 38:9, pages 1187-1193.
Crossref
Ashvin K. Patel & Paul N. Boyd. (1995) An improved assay for antibody dependent cellular cytotoxicity based on time resolved fluorometry. Journal of Immunological Methods 184:1, pages 29-38.
Crossref
Y. Bastion, N. Dhedin, B. Coiffier & P. Felman. (1995) The management of chronic lymphocytic leukemia – a case history. Annals of Oncology 6:1, pages 71-76.
Crossref
J R Salisbury, N T Rapson, J D Codd, M V Rogers & A B Nethersell. (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.. Journal of Clinical Pathology 47:4, pages 313-317.
Crossref
Geoffrey A. Pietersz, April Rowland, Mark J. Smyth & Ian F.C. Mckenzie. 1994. Advances in Immunology Volume 56. Advances in Immunology Volume 56 301 387 .
Judith Greenwood, Mike Clark & Herman Waldmann. (2005) Structural motifs involved in human IgG antibody effector functions. European Journal of Immunology 23:5, pages 1098-1104.
Crossref
Martin J. S. Dyer. 1993. Immunoconjugate Therapy of Hematologic Malignancies. Immunoconjugate Therapy of Hematologic Malignancies 161 180 .
Stephen P. Cobbold, Shixin Qin, Louise Y. W. Leong, Gilly Martin & Herman Waldmann. (2006) Reprogramming the Immune System for Peripheral Tolerance with CD4 and CD8 Monoclonal Antibodies. Immunological Reviews 129:1, pages 165-201.
Crossref
S.H. Lim & R.E. Marcus. (1992) Monoclonal antibody (MoAb) therapy in non-Hodgkin's lymphomas. Blood Reviews 6:3, pages 157-162.
Crossref
M.J.S. Dyer. (1992) Antibody therapy of malignancy. European Journal of Cancer 28:1, pages 276-280.
Crossref
Frederick R. Appelbaum. (1991) Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphoma. Hematology/Oncology Clinics of North America 5:5, pages 1013-1025.
Crossref
Stephen P. Cobbold. (1991) Monoclonal antibody therapy for the induction of transplantation tolerance. Immunology Letters 29:1-2, pages 117-121.
Crossref
Meng‐Qi Xia, Masahide Tone, Len Packman, Geoff Hale & Herman Waldmann. (2005) Characterization of the CAMPATH‐1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. European Journal of Immunology 21:7, pages 1677-1684.
Crossref
M. Brada. (1991) Impact of molecular biology on our understanding of non-Hodgkin lymphoma. European Journal of Cancer and Clinical Oncology 27:3, pages 315-320.
Crossref
Geoffrey Hale, Meng-Q. Xia, Helen P Tighe, Martin J. S. Dyer & Herman Waldmann. (1990) The CAMPATH-1 antigen (CDw52). Tissue Antigens 35:3, pages 118-127.
Crossref
M.J.S. Dyer. (1990) The new genetics and non-Hodgkin lymphoma. European Journal of Cancer and Clinical Oncology 26:10, pages 1099-1102.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.